Royal Bank of Canada Reiterates “Outperform” Rating for Aardvark Therapeutics (NASDAQ:AARD)

Royal Bank of Canada restated their outperform rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report released on Tuesday morning,Benzinga reports. Royal Bank of Canada currently has a $21.00 price objective on the stock.

Several other analysts have also recently commented on the company. Bank of America raised their target price on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Aardvark Therapeutics in a research note on Tuesday. Finally, Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $29.00 target price for the company.

Aardvark Therapeutics Stock Performance

NASDAQ AARD opened at $8.29 on Tuesday. Aardvark Therapeutics has a 52 week low of $6.79 and a 52 week high of $19.58.

Insider Activity

In other Aardvark Therapeutics news, CEO Tien-Li Lee purchased 16,542 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. This represents a 1.12 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Nelson Sun acquired 10,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at approximately $1,591,744. The trade was a 11.18 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.